Physician profile
Daniel Kovacs
NPI 1316262462
$757.49
in general payments reported to CMS, 2019-2025
15 companies · $49.97 in 2025
The $49.97 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $20.06 · 2021: $143 · 2022: $81.70 · 2023: $161 · 2024: $91.87 · 2025: $49.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263 · Consulting Fee: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.23 |
| Consulting Fee | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $177.09 | 2019-2021 | |
| Medtronic, INC. | $104.83 | 2021-2023 | Surgipro Ll |
| Merz North America, INC. | $100.10 | 2024-2025 | |
| Integra Lifesciences Corporation | $89.92 | 2021-2024 | Integra, Omnigraft, Surgimend |
| Eagle Pharmaceuticals, INC. | $47.99 | 2019 | |
| Smith+Nephew, INC. | $37.37 | 2023 | Grafix Pl |
| Organogenesis INC. | $35.50 | 2021-2023 | Puraply |
| Vertical Pharmaceuticals, LLC | $24.75 | 2023 | Dsuvia |
| Abbott Laboratories | $24.22 | 2019 | |
| Kci USA, INC. | $22.22 | 2021 | |
| Acera Surgical, INC. | $21.90 | 2022 | |
| Abbvie INC. | $20.24 | 2023 | |
| Aroa Biosurgery Incorporated | $19.80 | 2022 | |
| Polynovo North America LLC | $15.81 | 2021 | |
| Guard Medical INC. | $15.75 | 2023 | Npseal Medium, Npseal Large, Npseal (5) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.